Janux Therapeutics
JANX
Performance
About Janux Therapeutics
Janux Therapeutics is a biotechnology company developing novel immunotherapies that selectively modulate T cells to fight cancer and autoimmune diseases without systemic safety issues. The company focuses on precision-engineered bispecific T cell engagers using TRACTr and TRACIr modalities, along with the ARM platform, to engage the immune system in targeted ways. Its development programs center on cancer and autoimmune indications, with clinical trials such as JANX007 for prostate cancer (mCRPC) and other TRACTr-based assets. Janux positions itself as advancing targeted immunotherapies with an emphasis on safety and tumor-activated mechanisms.
Recent News
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
First Patient Receives JANX014 Dose in Janux’s Trial for mCRPC
Janux Hires CMO After T Cell Engager Deal with Bristol Myers; A Batch of Appointments at Lexeo
Bristol Myers Signs Deal with Janux on T Cell Engager for $50M Upfront
Janux Therapeutics Halts Development of EGFR‑Targeted TRACTr Candidate JANX008
Recent Deals
No recent deals for this company.